Gilead Sciences Inc. BDR | |
Stock Exchange | Brazilian Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
- |
Public Float |
- |
Gilead Sciences Inc. | |
Stock Exchange | Xetra Stock Exchange |
EPS |
EUR3.9 |
Market Cap |
EUR78.15 B |
Shares Outstanding |
1.3 B |
Public Float |
1.3 B |
Gilead Sciences Inc. | |
Stock Exchange | Mexican Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.3 B |
Public Float |
1.3 B |
Gilead Sciences Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$4.54 |
Market Cap |
$87.14 B |
Shares Outstanding |
1.27 B |
Public Float |
1.27 B |
Gilead Sciences Inc. | |
Stock Exchange | SIX Swiss Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.3 B |
Public Float |
1.3 B |
Address |
333 Lakeside Drive Foster City California 94404 United States |
Employees | - |
Website | http://www.gilead.com |
Updated | 07/08/2019 |
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. It also offers other pharmaceutical products under the Letairis, Ranexa, AmBisome, and Zydelig brands. |